Therapeutic effect and mechanism of urinary kallidinogenase combined with edaravone on acute cerebral infarction
-
摘要: 目的 观察依达拉奉、尤瑞克林对急性脑梗死(ACI)的临床疗效及其神经保护作用机制。 方法 选择92例ACI患者,随机分为对照组和观察组。观察组给予依达拉奉联合尤瑞克林,对照组仅给予依达拉奉治疗。比较2组血流变学指标、血清肿瘤坏死因子α(TNF-α)、白介素-8(IL-8)、基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF),评定比较2组的ESS评分、BI及临床疗效。 结果 治疗后,2组的各项血液流变学指标均较治疗前明显下降(P<0.01)。观察组下降更加显著(P<0.01)。2组的血清TNF-α、IL-8、MMP-9水平均较治疗前显著下降,VEGF水平显著上升(P<0.01),观察组TNF-α、IL-8、MMP-9下降更为显著,VEGF上升更加显著(P<0.01)。治疗后,对照组及观察组的ESS、BI评分较治疗前显著提高(P<0.01),且观察组提高程度显著优于对照组(P<0.01)。观察组总有效率为89.1%,显著高于对照组的71.7%(P<0.01)。 结论 尤瑞克林联合依达拉奉用于ACI治疗,可更有效地降低血清炎症因子水平,抑制炎症损伤,改善脑组织供血,促进神经功能的恢复,其临床疗效更加优于单纯使用依达拉奉。Abstract: Objective To observe the clinical efficacy of urinary kallidinogenase combined with edaravone in the treatment of the acute cerebral infarction(ACI) and its mechanism of neural protection. Methods Total 92 cases of ACI were randomly divided into control group and observation group. The observation group was given edaravone combined with urinary kallidinogenase,while the control group was given edaravone,the course was 14 days. The blood rheology index,serum TNF-α,IL-8 and MMP-9 and VEGF,ESS and BI score and the clinical efficacy were compared between the two groups. Results After the treatment,the indexes of the two groups were significantly decreased(P < 0. 01). Compared with the control group,the observation group decreased more significantly(P < 0. 01). After the treatment,the levels of serum TNF-α,IL-8 and MMP-9 in both groups decreased significantly,VEGF levels increased significantly(P < 0. 01),and these indexes in the observation group decreased more significantly and VEGF increased more significantly(P < 0. 01).After the treatment,the ESS and BI scores of the two groups were significantly higher than those before treatment(P <0. 01),and the improvement of the observation group was significantly better than the control group(P < 0. 01). The total effective rate of the observation group was 89. 1%,which was significantly higher than that of the control group(P <0. 01). Conclusion Urinary kallidinogenase combined with edaravone can be better in the treatment of ACI as compared with single edaravone by decreasing the serum levels of inflammatory cytokines,inhibiting the inflammatory injury,improving the blood supply in brain tissues,and promoting the recovery of neurological function.
-
Key words:
- Urinary kallidinogenase /
- Edaravone /
- Acute cerebral infarction
点击查看大图
计量
- 文章访问数: 88
- HTML全文浏览量: 23
- PDF下载量: 0
- 被引次数: 0